Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 07 Nov 2018 Status changed to discontinued as per PI's request
- 31 Aug 2018 Biomarkers information updated
- 07 May 2018 Status changed from active, no longer recruiting to completed.